0.81 USD
▼-0.03-0.18%
盘后 0.81 -0.04%
2026-08-03
市值
$25.41M
市盈率
—
EPS
-0.75
股息率
—
52 周区间
0.81 – 1.81
成交量
92.12K
Beta
-0.01
目标价
5.00
52W 低 0.8152W 高 1.81
价格走势
公司简介
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody...